Evaluation of the Effect of Ondansetron as Additional Drug on Reducing Negative Symptoms in Hospitalized and Outpatient with Schizophrenia Disorders
Phase 3
- Conditions
- Schizophernia.Schizophrenia, unspecifiedF20.9
- Registration Number
- IRCT20190321043096N1
- Lead Sponsor
- Gorgan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
age of 18-65
No physical illness
No alcohol or drug abuse
The absence of pregnancy and lactation in women
PANSS score of more than 15
Acceptance of written consent
Exclusion Criteria
Drug abuse or alcohol abuse
Breastfeeding and pregnancy women
The need for other psychotropic drugs during the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Earn score 7-49 in the test of N-PANSs. Timepoint: Before starting the study and 6, 8 and 12 weeks after starting the study. Method of measurement: Based on DSM-5.
- Secondary Outcome Measures
Name Time Method egative symptoms of schizophrenia. Timepoint: Weeks of 0, 6, 8 and 12. Method of measurement: Evaluation Scale of PANSS.